Try
NOVAVAX INC
NVAXUnited States
75 filed reports · 667 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
75 reports · Sep 2012 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 40 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 42 | 6,155 | Sep 2012 to Jun 2026 |
| Current · 8-KSEC EDGAR | 18 | 40 | Sep 2016 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 14 | 5,904 | Dec 2012 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 1 | Dec 2020 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 6, 2026 | 2 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 347 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 6, 2026 | 2 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 221 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 26, 2026 | 2 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 26, 2026 | 963 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 6, 2025 | 2 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 239 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 160 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 6, 2025 | 2 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 164 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | May 8, 2025 | 2 | Open |
Financial data
667 concepts · 12,100 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial651 concepts · 11,682 facts · Jul 2008 to Jul 2026
- Revenue79 · Dec 2010 to Jun 2026
- Cash and cash equivalents at carrying value77 · Dec 2010 to Jun 2026
- Allocated share based compensation expense76 · Dec 2010 to Jun 2026
- Comprehensive income net of tax76 · Dec 2010 to Jun 2026
- Costs and expenses76 · Dec 2010 to Jun 2026
- Net income loss76 · Dec 2010 to Jun 2026
- Operating income loss76 · Dec 2010 to Jun 2026
- Research and development expense76 · Dec 2010 to Jun 2026
- Depreciation and amortization75 · Dec 2010 to Jun 2026
- Increase decrease in accounts payable and accrued liabilities75 · Dec 2010 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets75 · Dec 2010 to Jun 2026
- Other noncash income expense75 · Dec 2010 to Jun 2026
- Share based compensation75 · Dec 2010 to Jun 2026
- Share based compensation arrangement by share based payment award options exercises in period total intrinsic value75 · Dec 2010 to Jun 2026
- Stockholders equity (US GAAP)74 · Dec 2010 to Jun 2026
- Capital expenditures incurred but not yet paid73 · Dec 2010 to Dec 2025
- Common stock shares authorized73 · Dec 2011 to Jun 2026
- Common stock shares outstanding73 · Dec 2011 to Jun 2026
- Proceeds from issuance of common stock73 · Dec 2010 to Dec 2025
- Accounts payable current72 · Dec 2011 to Jun 2026
- Accrued liabilities current72 · Dec 2011 to Jun 2026
- Accumulated other comprehensive income loss net of tax72 · Dec 2011 to Jun 2026
- Additional paid in capital72 · Dec 2011 to Jun 2026
- Assets72 · Dec 2011 to Jun 2026
Product6 concepts · 250 facts · Dec 2016 to Jun 2026
- Revenue216 · Dec 2016 to Jun 2026
- Increase decrease in contract with customer liability11 · Dec 2023 to Dec 2025
- Product11 · Dec 2023 to Dec 2025
- Database lock of an Existing Phase 2/3 clinical trial6 · Mar 2025 to Jun 2026
- Licensed COVID-19 Products And Royalty Payments4 · Dec 2024 to Dec 2025
- CEPI Grant Funding2 · Dec 2020
Segment6 concepts · 70 facts · Dec 2022 to Jun 2026
- Cost of revenue (US GAAP)14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Revenue14 · Dec 2022 to Jun 2026
- Selling general and administrative expense14 · Dec 2022 to Jun 2026
- Segment reporting other item amount12 · Dec 2022 to Dec 2025
- Reportable Segment2 · Jun 2025 to Jun 2026
Geography2 concepts · 58 facts · Dec 2021 to Jun 2026
- Revenue54 · Dec 2022 to Jun 2026
- Property, Plant & Equipment, Net4 · Dec 2021 to Dec 2024
Guidance2 concepts · 40 facts · Nov 2016 to Aug 2026
- Revenue Guidance38 · Mar 2022 to Aug 2026
- Free Cash Flow Guidance2 · Nov 2016
Segments
378 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service16 members · 250 facts
- Product95 · Dec 2020 to Jun 2026
- Grant38 · Dec 2016 to Dec 2025
- Royalties And Other18 · Dec 2019 to Mar 2024
- Licensing Royalties And Other16 · Dec 2022 to Jun 2026
- Sales Based Royalties15 · Mar 2021 to Dec 2023
- Government Contract14 · Dec 2016 to Sep 2021
- Nuvaxovid Sales13 · Dec 2023 to Jun 2026
- Supply Sales13 · Dec 2023 to Jun 2026
- Database Lock Of An Existing Phase23 Clinical Trial10 · Dec 2024 to Jun 2026
- Milestone Payments7 · Dec 2021 to Dec 2023
- Royalty4 · Jun 2020 to Sep 2021
- License Fees3 · Mar 2024 to Sep 2024
- License1 · Jun 2024
- License Fees And Sales Based Royalties1 · Dec 2024
- Transfer Of Technology1 · Jun 2024
- Transition Services1 · Jun 2024
Statement business segments1 member · 70 facts
- Reportable70 · Dec 2022 to Jun 2026
Statement geographical6 members · 58 facts
- Europe14 · Dec 2022 to Jun 2026
- Rest Of The World14 · Dec 2022 to Jun 2026
- US14 · Dec 2022 to Jun 2026
- CA8 · Mar 2024 to Jun 2026
- Cz4 · Dec 2021 to Dec 2024
- Rest Of North America4 · Dec 2022 to Dec 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 6, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.